<SEC-DOCUMENT>0001564590-20-043044.txt : 20200910
<SEC-HEADER>0001564590-20-043044.hdr.sgml : 20200910
<ACCEPTANCE-DATETIME>20200910073519
ACCESSION NUMBER:		0001564590-20-043044
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200910
FILED AS OF DATE:		20200910
DATE AS OF CHANGE:		20200910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zai Lab Ltd
		CENTRAL INDEX KEY:			0001704292
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38205
		FILM NUMBER:		201167741

	BUSINESS ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862161632588

	MAIL ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zlab-6k_20200910.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
zlab-6k_20200910.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 6-K </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13A-16 OR 15D-16</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the month of September 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission Filing Number: 001-38205</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZAI LAB LIMITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Translation of registrant&#8217;s name into English)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive office) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:66.67%;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form 20-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font> Form 40-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:504pt;;">
<tr>
<td style="width:54pt;"></td>
<td style="width:31.5pt;"></td>
<td style="width:418.5pt;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="zlab-ex991_6.htm"><font style="text-decoration:underline;">Press release issued September 10, 2020</font></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:53.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZAI LAB LIMITED</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:104.16%;">
<tr>
<td valign="middle"  style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle"  style="width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="bottom"  style="width:34.28%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Samantha Du</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samantha Du</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:51.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: September 10, 2020</p></td>
<td valign="bottom"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>zlab-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
zlab-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk532369699"></a><img src="gptuybq22ujf000001.jpg" title="" alt="" style="width:160px;height:55px;"><font style="font-size:18pt;font-family:Arial;">&nbsp;&nbsp;</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab Announces NMPA Approval of ZEJULA&#174; (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;font-style:italic;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">- ZEJULA was recommended as a monotherapy first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer in the Ovarian Cancer PARP Inhibitor Clinical Guidelines published by Gynecological Oncology, Chinese Medical Association</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHANGHAI and SAN FRANCISCO, September 10, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its supplemental New Drug Application (sNDA) for ZEJULA<font style="Background-color:#FFFFFF;font-size:11.5pt;">&#174;</font> (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We believe ZEJULA is a potential best-in-class PARP inhibitor. It is the first and only PARP inhibitor approved anywhere globally, including in China as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings,&#8221; said Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab. &#8220;The NMPA&#8217;s rapid approval of our sNDA for ZEJULA underscores the unmet medical needs it serves and further enables Zai Lab to make a meaningful impact on the way ovarian cancer is treated in China.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The approval of ZEJULA for the first-line maintenance treatment setting represents an opportunity to fundamentally change how women with ovarian cancer will be treated in China and a new standard of care for these patients,&#8221; said Dr.&#160;Lingying Wu, Director of the&#160;Department of Gynecologic Oncology&#160;of the&#160;Cancer Hospital&#160;of&#160;China Academy of Medical Sciences. &#8220;In addition to its compelling efficacy data as monotherapy for all-comer patients, ZEJULA also has the convenience of once-daily dosing, excellent safety profile and attractive pharmacokinetic properties, including its ability to cross the blood brain barrier.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="_Hlk50543297"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZEJULA&#8217;s sNDA for the first-line maintenance treatment setting was accepted by the NMPA in March 2020, and was granted priority review status in April 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Ovarian Cancer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Ovarian cancer is one of the most common gynecologic cancers in China with approximately 52,000 newly diagnosed cases and 23,000 deaths in China per year. While platinum-based </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chemotherapy is effective at inducing an initial response in ovarian cancer, the disease will recur in the majority of women. Effective treatment options for patients with platinum-sensitive recurrent ovarian cancer remain limited. New agents that prolong the duration of response following platinum-based treatment and delay the inevitable relapse of ovarian cancer will benefit patients with ovarian cancer in China.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About ZEJULA (Niraparib)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ZEJULA (niraparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced and recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to first and second-line platinum-based chemotherapy. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The PRIMA study conducted by Zai Lab&#8217;s partner GlaxoSmithKline plc (GSK) demonstrated </font>significant progression-free survival (PFS) improvement when given as monotherapy in women with first-line platinum responsive ovarian cancer, resulting in a 38% reduction in the risk of disease progression or death in the overall study population. Clinically meaningful reduction in risk of disease progression or death was further demonstrated with hazard ratios (HRs) of 0.40, 0.43 and 0.68 for BRCA mutant, HRD positive and HRD negative tumors, respectively. This study showed ZEJULA as the first PARP inhibitor to significantly improve PFS in this setting, regardless of biomarker status.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Zai Lab has several studies ongoing or completed in Chinese patients with ovarian cancer:</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><font style="color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;">&#9679;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">In November 2019, Zai Lab completed patient enrollment of its self-sponsored Phase III PRIME study evaluating ZEJULA as a first-line maintenance therapy in ovarian cancer patients who are in a complete or partial response to first-line platinum-based chemotherapy. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.03%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><font style="color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;">&#9679;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">In May 2020, Zai Lab announced positive top-line results from its self-sponsored Phase III NORA study of ZEJULA as maintenance therapy for Chinese patients with platinum-sensitive, recurrent ovarian cancer. The full results from the NORA study will be presented at European Society for Medical Oncology (ESMO) 2020 Virtual Congress on September 19, 2020. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><font style="color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;">&#9679;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="Background-color:#FFFFFF;font-family:Arial;">In August 2020, the first patient was dosed in the registrational bridging trial for late-line ovarian cancer treatment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><font style="color:#000000;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;">&#9679;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="Background-color:#FFFFFF;font-family:Arial;">Zai Lab also conducted a Phase I pharmacokinetic (PK) study of ZEJULA in Chinese patients with ovarian cancer. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;margin-left:3.03%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ZEJULA is also being evaluated in China in a Phase Ib dose escalation and expansion clinical study, in combination with tebotelimab (PD-1 x LAG-3 DART molecule) for the treatment of patients with advanced or metastatic gastric cancer who failed prior treatment.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Zai Lab has a collaboration, development and license agreement with GSK for the development and commercialization of ZEJULA in Mainland China, Hong Kong and Macau. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Important Safety Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>The most common side effects for patients taking ZEJULA include heart not beating regularly, nausea, constipation, vomiting, pain in the stomach area, mouth sores, diarrhea, indigestion or heartburn, dry mouth, tiredness, loss of appetite, urinary tract infection, shortness of breath, </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cough, rash, changes in liver function or other blood tests, pain in your joints, muscles, and back, headache, dizziness, change in the way food tastes, trouble sleeping, anxiety, sore throat and changes in the amount or color of your urine. Other potential serious side effects include bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of blood cancer called Acute Myeloid Leukemia (AML), symptoms of low blood cell counts (which can be a sign of serious bone marrow problems) and high blood pressures. Patients should take a few medical tests before they are treated with ZEJULA. Healthcare providers should periodically monitor their patients&#8217; blood cell counts and blood pressures.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Zai Lab</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab (NASDAQ:ZLAB) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China&#8217;s pharmaceutical market and address unmet medical needs, Zai Lab&#8217;s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab&#8217;s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information about the Company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for commercializing ZEJULA in China and other statements containing words such as &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221; and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab's expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab&#8217;s ability to obtain additional future funding, (2) Zai Lab&#8217;s results of clinical and pre-clinical development of its drug candidates, (3) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab&#8217;s drug candidates, (4) Zai Lab&#8217;s ability to generate revenue from its drug candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on general economic, regulatory and political conditions and (6) other factors discussed in Zai Lab's Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed on April 29, 2020, and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab&#8217;s expectations and assumptions to change and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab&#8217;s views as of any date subsequent to the date of this press release.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">For more information, please contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZAI LAB CONTACTS:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab<font style="font-weight:normal;"><br />Billy Cho, CFO<br />+86 137 6151 2501 <br /></font><font style="text-decoration:none;font-weight:normal;">billy.cho@zailaboratory.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media: Ryo Imai / Robert Flamm, Ph.D.<br />Burns McClellan, on behalf of Zai Lab<br />212-213-0006 ext. 315 / 364</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rimai@burnsmc.com / rflamm@burnsmc.com<font style="text-decoration:underline;"> </font><font style="text-decoration:underline;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors: Pete Rahmer / Mike Zanoni<br />Endurance Advisors, on behalf of Zai Lab<br />415-515-9763 / 610-442-8570</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com<font style="text-decoration:underline;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gptuybq22ujf000002.jpg" title="" alt="" style="width:186px;height:44px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zai Lab Limited</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gptuybq22ujf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gptuybq22ujf000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #Q @0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ1]MMO\ GNG_ 'V*HQY9=B:BHQ<VYZ3+_P!]4Y9$?[K@T$V8ZBC-% !1110
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MTFOG8^KO^"Q'QI_;^^'T'P]T;]FV3QEI_AF3PW#)=:CX3MYW:6?8N4E:('
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M@.<[17T&#K2Q&&C5?5'X7QMD='AWBC%9?2=X0DU'O;=7^1)11174?+!1110
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ME#UXN4;:>:^8Q_\ O<_\3/Z:X-_Y)/!?]>H?^DH_;;_@V0RW[(GCC_LI,_\
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MXS7%CL9]3P[FM]C[3@+A&7&7$$,#*?)!)RG*VT5N?1/Q9_X.:?@?X:U]M/\
M@_\  77O$MG'(Z-?ZEJ4>GA\-@,B[)25(Y&[:>F0.@Y0_P#!T39YX_9 N/\
MPM$_^1:I_LK?\&V'A+QC\,-/\9_M)_&?Q!9:MJMG%<KI/AF&&W6Q#KGRY&N(
MY3(P!&<*FT@C!ZGU _\ !LC^QX!Q\<?B7_X':?\ _(=>0GQ%4CSKE5]EIH?K
M5:/T?\OJ/#3C6J2@[.2YFG;KHU^1YY_Q%$V1X_X8\N?_  M$_P#D6D/_  =%
M66.?V/KG_P +1?\ Y%KT3_B&/_8_/_-</B5_X'6'_P AT'_@V-_9!/3XX_$K
M_P #M/\ _D.CEXB_FC^'^1G];^CU_P ^:W_DW_R1YTG_  =#V3-B3]D"YVYY
MQXR7_P"1:]-_;P_:R\*_MK?\$>M=^.OA'0+O2H+]1'+I]\Z,T,B2 , 5ZCT.
M!GT%5A_P;'_L?C&_XV_$EAZ?;M/Y_P#).M__ (*/_LO_  S_ &0/^"26O_!/
MX40W:Z3IL:LLE_<F6::1G!9V8]R>P  [ 5M;-?J]3ZTU;E>QY]2OX85L\R]<
M-TZD:OM8W<KVM?S;/G__ (-BACQC\2N?^7&U_P#0C7SK_P %=!G_ (*KZQQ_
MS%-/_FM?17_!L5_R.'Q)/_3G;?\ H5?.?_!7=@G_  56UAV; &J:?R?JM>=/
M_D2T?\2_,_0,%_R>3,_^O,O_ $E'[Z?"HG_A6^@_]@FW_P#1:UTA_AKG?A4P
M?X;Z"5Y_XD]O]T_],UKHB#\O%?6Q^%'\FXK_ 'JI_B?YCJ***HYQI_BKX;_X
M.#A_QKXU8 ?\QRR_FU?<A/WJ^&_^#@XY_P""?&JX/_,<LOYM7)C/]SGZ,^KX
M'_Y*_ _]?(?FCPC_ (-A?^2>_$CC_F.P?^B5K]6XONU^4G_!L*?^+>_$CG_F
M.P?^B5K]6XON5AE/_(NI^A[?BQ_R7V-_Q+\D.HHHKTC\Y"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** # ZXI&&1@4;E]:1V5EQF@""YN(;
M:%I9Y JJI+,W0#UK\%O^"ZG[>]Q^TC\>F^!O@776D\(^#IC'-]GF;RKV]_B8
MKM (3H/O#/((K](_^"S'[=MM^Q[^S5=:+X9O]GBSQ6DEAHJKOW1 K\\V5*D;
M5Z'<#GUK^>NZNKJ]NI+^]GDFFFF,DTLK$M(Q.2Q/<DDYSU-?*\19AR0^KP>K
MW\E_P3^HOH^\!_6L3+B#%P]R&E.^SEUE\MD1[B3CBOU-_P"#=_\ 83/BKQ3=
M?M@_$#2)!:Z:S6OA>.99%$DG\<W("L!T!!(K\\?V8?@#XJ_:=^.?A[X*^#K=
MY+G6KY8I9%5<119R[_,R]!GC(_&OZ9OV;_@1X,_9P^#NA?!_P)I<-M8Z/9)%
MF&%$,KX^:1@H&68Y)/?OFN+AW ^VK>WDM%^?_ /MO'[CK^Q\I62X:?[RLO>M
MNH=OG^1W^T)&% KF?C5\GPF\2$#_ )@=U_Z*:NG;E>!7,_&K_DD_B3_L!W7_
M **:OMI?"S^,,'_OE/\ Q+\S^5'Q<S'Q9JCDG=_:,_\ Z&:H.3MQ6AXN8?\
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MCO\ ?)_XF?TSP7_R2>"_Z]0_])1^VG_!L>P_X9$\<''_ #4B8_\ E/L:J?\
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MOW^ZY]%6\/\ PGS3$2Q&%SQ4H2N^625XWZ:V?X?,_<+_ (>*?L#?]'G?"_\
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M+R:XT^.:YU+2?"49LI6*\O$S3@F,]L]JX']G3_@M[\;_ (E^-/&5AKW[$'Q
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M4>=V2VM?H2T445T'AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%-GC26)HY!E2,,".M.H/(YH \TNOV3?V8]4NY-0U+]GGP5+<32%YII/"]JS2
M,3DDDQY))Y)/.:7_ (8__95VY_X9P\#_ /A*VG_QNO1MN3P*,$-DUFXP[;^1
MV1S#,(Q25:>G]Y_YGG/_  Q]^RK_ -&X>"/_  EK3_XW1_PQ]^RK_P!&X>"/
M_"6M/_C=>D;&]11L;UHY*?\ +^ ?VEF/_/Z?_@3_ ,SS?_AC[]E;_HW#P1_X
M2UI_\;H_X8^_96_Z-P\$?^$K:?\ QNO2-C>M)L;UHY:?\OX!_:68_P#/Z?\
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M)MON]7][.>^'OPO^'GPHTI_#_P -/ VE>'[&:Y>YFL])L8[>-YG/S.50 ;B
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M **** "BBB@ HHHH **** "BBB@ HHHH *.O4444 %%%% !@>E%%% !1110
M4444 %'3H*** "C&>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH /?%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gptuybq22ujf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gptuybq22ujf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M +L# 2(  A$! Q$!_\0
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MI=E^H'3\:?,K7(5"JY^S47S=K:G1TE<WHWCSP[KTK0V5]^_52WE2H49@!DD
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M_2OG;X<A1\0M)"G*B1P#ZC8U*=-0G&QIA,=4Q6$K*KNEO\F1?$7_ )'O6O\
MKH/_ $ 5ZJ/^2F>&?^P*_P#2O*OB+_R/>M?]=!_Z *]4UNSU>QU/P_XETK3F
MU(6UD;>>V1@K[6 (*TX?%+U)QMO84(WWBU_Y*CT&BN!_X3SQ'_T(.J?]_/\
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MW\.3ZO9ZA>-=Q36SX*[NJL,'I26]WL74?-#V<7[UOYE_-WVV.P_X1/P]_P!
M33__  '7_"N6O=,LM&^*?AS^S+6*T6ZM[A)EA4*' 7(R![T__A//$7_0@ZI_
MWW_]C3-+77?$_C;3]:O]$ETFSTV&556=P7D=QC@8'&/;M5-Q>QA3A6I\TJLM
M+/[2?332_<]!HHHK4\P**** "BBB@ IDLB11/)(X1$4LS$\ #J:?63XCT9_$
M&BS:8M[):)/@221J"Q7NO/K294$G)*3LCY^\:>)7\4^))KP,PM(_W5LI'W8P
M?O8]3U_*O1-&^)_A/0]'M=-M+341#;H%!\E<L>Y/S=2<FC_A25A_T&KO_OTM
M'_"DK#_H-7?_ 'Z6N:,:J;?<^FK8G+*M*-*4GRQVL1>*M0M/B1X/NKK1K>Y\
M_2)5E*2H 74@[@ "<\<_A7(> ?'3>$IYH;B%Y].N"&=4/S1MTW+GKQU'L*]?
M\'>#(/!T-W%!>2W/VIU8F10-N 1V^M<[XD^$VEW]U)?6%U)IYD)9XEC#H3U)
M R,?RJI0GI-;F&'QN#2GA9W=-O1_UYF7XN^+-G>Z--8Z%'<>;<(4>>5-@C4]
M<#N<<>U<;\./^2@:0!_??_T6U>A>'?A)IEM*MY?7DEZ0/DC,81 <=2,G./2K
MOA_X56GA_7+75(]5N)GMR2$>-0&RI';ZU/)4E)2D:_7,!0H5*%&^JW[L\K^(
MO_(]ZU_UT'_H KVC6/$<_A[2=',-M%/]IC6,*SE3D)GTQC /4UDZ_P#">SU_
M6[S4Y-5N87N6W%%C4A> ._TKI-3\)V&K/I9NVE9; %0H<J) 5V\X/'KQ5PA*
M+D^YR8O&8>M3HPWY5K]R_4RO"WC2\\1:C';/8P6ZM$TQ/FEB5!QQ@>I'7%=1
MJM[_ &=I-U>A-_D1-)M)QG SC-9&G>"]*TK6X]1LUDB$41BCA#L5!)Y/)Y^G
M2MC4[+^T=,N+/S6B\^,IO7JN>]:J]M3S*KHNHG!>Z>?CXI7&X$Z3%M+NN//.
MX;0W7CV_6O2(VWQJW3< :XO_ (5KIPN)Y1?76V2-DC4D'RV*J-_N?ESC&.:[
M.)#'"D9<N54*6/4X'6E'F^T7B70=O8JQPVK?$"YTV_FA%E:M''*\98SD,NU]
M@)&/XCG&,\#FNE\.ZM/K%@]Q/%!$RR%-D4N_&,=?2LN[\$B[OI+@ZG)Y32O*
MMO) CHK/U.".3R<$]*U?#^A_V!8/:+=R7"&0NN]0-@./E'M37-?451T/9+D^
M+YE#Q1XHFT"XLH(;6&=[ML+YDQ3 !^8X"GC'_P"JJV@>,9]9U-;:2QC@AF+F
MWE\QB)50#)4E &Y/J.*T]9\,P:W?VEW-<2QM:@A @4]2,GD'TQ19>'([+67O
HUGS'ND>*!8PJHTFW<<]_NCT[T>]<%*A[*S7O&V*6BBJ.4**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
